Frontiers in Endocrinology (Oct 2023)
The short- and long-term readmission of four major categories of digestive system cancers: does obesity or metabolic disorder matter?
- Yan Li,
- Yan Li,
- Yan Li,
- Yan Li,
- Yan Li,
- Xiaoqin Wu,
- Yongfeng Song,
- Yongfeng Song,
- Yongfeng Song,
- Yongfeng Song,
- Yongfeng Song,
- Yongfeng Song,
- Peipei Wang,
- Bofei Zhang,
- Bingzhou Guo,
- Ziwei Liu,
- Yafei Wu,
- Yafei Wu,
- Yafei Wu,
- Yafei Wu,
- Yafei Wu,
- Yafei Wu,
- Shanshan Shao,
- Shanshan Shao,
- Shanshan Shao,
- Shanshan Shao,
- Shanshan Shao,
- Shanshan Shao,
- Yiping Cheng,
- Yiping Cheng,
- Yiping Cheng,
- Yiping Cheng,
- Yiping Cheng,
- Yiping Cheng,
- Honglin Guo,
- Honglin Guo,
- Honglin Guo,
- Honglin Guo,
- Honglin Guo,
- Honglin Guo,
- Xiude Fan,
- Xiude Fan,
- Xiude Fan,
- Xiude Fan,
- Xiude Fan,
- Xiude Fan,
- Jiajun Zhao,
- Jiajun Zhao,
- Jiajun Zhao,
- Jiajun Zhao,
- Jiajun Zhao,
- Jiajun Zhao
Affiliations
- Yan Li
- Department of Endocrinology, Shandong Provincial Hospital, Shandong University, Jinan, China
- Yan Li
- Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, Shandong, China
- Yan Li
- Shandong Institute of Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Yan Li
- Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Yan Li
- Shandong Engineering Research Center of Stem Cell and Gene Therapy for Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Xiaoqin Wu
- Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, United States
- Yongfeng Song
- Department of Endocrinology, Shandong Provincial Hospital, Shandong University, Jinan, China
- Yongfeng Song
- Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, Shandong, China
- Yongfeng Song
- Shandong Institute of Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Yongfeng Song
- Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Yongfeng Song
- Shandong Engineering Research Center of Stem Cell and Gene Therapy for Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Yongfeng Song
- Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Peipei Wang
- Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Bofei Zhang
- Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Bingzhou Guo
- College of Artificial Intelligence and Big Data for Medical Sciences, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
- Ziwei Liu
- Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Yafei Wu
- Department of Endocrinology, Shandong Provincial Hospital, Shandong University, Jinan, China
- Yafei Wu
- Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, Shandong, China
- Yafei Wu
- Shandong Institute of Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Yafei Wu
- Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Yafei Wu
- Shandong Engineering Research Center of Stem Cell and Gene Therapy for Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Yafei Wu
- Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Shanshan Shao
- Department of Endocrinology, Shandong Provincial Hospital, Shandong University, Jinan, China
- Shanshan Shao
- Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, Shandong, China
- Shanshan Shao
- Shandong Institute of Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Shanshan Shao
- Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Shanshan Shao
- Shandong Engineering Research Center of Stem Cell and Gene Therapy for Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Shanshan Shao
- Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Yiping Cheng
- Department of Endocrinology, Shandong Provincial Hospital, Shandong University, Jinan, China
- Yiping Cheng
- Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, Shandong, China
- Yiping Cheng
- Shandong Institute of Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Yiping Cheng
- Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Yiping Cheng
- Shandong Engineering Research Center of Stem Cell and Gene Therapy for Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Yiping Cheng
- Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Honglin Guo
- Department of Endocrinology, Shandong Provincial Hospital, Shandong University, Jinan, China
- Honglin Guo
- Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, Shandong, China
- Honglin Guo
- Shandong Institute of Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Honglin Guo
- Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Honglin Guo
- Shandong Engineering Research Center of Stem Cell and Gene Therapy for Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Honglin Guo
- Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Xiude Fan
- Department of Endocrinology, Shandong Provincial Hospital, Shandong University, Jinan, China
- Xiude Fan
- Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, Shandong, China
- Xiude Fan
- Shandong Institute of Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Xiude Fan
- Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Xiude Fan
- Shandong Engineering Research Center of Stem Cell and Gene Therapy for Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Xiude Fan
- Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Jiajun Zhao
- Department of Endocrinology, Shandong Provincial Hospital, Shandong University, Jinan, China
- Jiajun Zhao
- Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, Shandong, China
- Jiajun Zhao
- Shandong Institute of Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Jiajun Zhao
- Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Jiajun Zhao
- Shandong Engineering Research Center of Stem Cell and Gene Therapy for Endocrine and Metabolic Diseases, Jinan, Shandong, China
- Jiajun Zhao
- Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- DOI
- https://doi.org/10.3389/fendo.2023.1214651
- Journal volume & issue
-
Vol. 14
Abstract
PurposePatients with digestive system cancers (DSCs) are at a high risk for hospitalizations; however, the risk factors for readmission remain unknown. Here, we established a retrospective cohort study to assess the association between metabolic obesity phenotypes and readmission risks of DSC.Experimental designA total of 142,753 and 74,566 patients at index hospitalization were ultimately selected from the Nationwide Readmissions Database (NRD) 2018 to establish the 30-day and 180-day readmission cohorts, respectively. The study population was classified into four groups: metabolically healthy non-obese (MHNO), metabolically healthy obese (MHO), metabolically unhealthy non-obese (MUNO), and metabolically unhealthy obese (MUO). Multivariate Cox regression analysis was used to estimate the effect of metabolic obesity phenotypes on DSC readmission.ResultsThe MUNO phenotype had 1.147-fold (95% CI: 1.066, 1.235; p < 0.001) increased 180-day readmission risks in patients with neoplasm of the upper digestive tract. The MUNO phenotype had 1.073-fold (95% CI: 1.027, 1.121; p = 0.002) increased 30-day readmission risks and 1.067-fold (95% CI: 1.021, 1.115; p = 0.004) increased 180-day readmission risks in patients with neoplasm of the lower digestive tract. The MUNO and MUO phenotypes were independent risk factors of readmission in patients with liver or pancreatic neoplasm. Metabolic obesity status was independently associated with a high risk of severe and unplanned hospitalization within 30 days or 180 days.ConclusionBoth obesity and metabolic abnormalities are associated with a high risk for the poor prognosis of DSC patients. The effect of metabolic categories on the short- or long-term readmission of liver or pancreas cancers may be stronger than that of obesity.
Keywords